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To investigate cytogenetic evolution after upfront autologous stemcell transplantation for newly diagnosed myeloma we retrospec-tively analyzed fluorescence in situ hybridization results of 128
patients with paired bone marrow samples from the time of primary
diagnosis and at relapse. High-risk cytogenetic abnormalities (deletion
17p and/or gain 1q21) occurred more frequently after relapse (odds ratio:
6.33; 95% confidence interval: 1.86-33.42; P<0.001). No significant
changes were observed for defined IGH translocations [t(4;14); t(11;14);
t(14;16)] or hyperdiploid karyotypes between primary diagnosis and
relapse. IGH translocations with unknown partners occurred more fre-
quently at relapse. New deletion 17p and/or gain 1q21 were associated
with cytogenetic heterogeneity, since some de novo lesions with different
copy numbers were present only in subclones. No distinct baseline char-
acteristics were associated with the occurrence of new high-risk cytoge-
netic abnormalities after progression. Patients who relapsed after novel
agent-based induction therapy had an increased risk of developing high-
risk aberrations (odds ratio 10.82; 95% confidence interval: 1.65-127.66;
P=0.03) compared to those who were treated with conventional
chemotherapy. Survival analysis revealed dismal outcomes regardless of
whether high-risk aberrations were present at baseline (hazard ratio,
3.53; 95% confidence interval: 1.53-8.14; P=0.003) or developed at
relapse only (hazard ratio, 3.06; 95% confidence interval: 1.09-8.59;
P=0.03). Our results demonstrate cytogenetic evolution towards high-
risk disease after autologous transplantation and underline the impor-
tance of repeated genetic testing in relapsed myeloma (EudraCT number
of the HD4 trial: 2004-000944-26).
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ABSTRACT
Introduction
Multiple myeloma (MM) is a genetically complex and heterogeneous disease.1,2 At
the chromosomal level, MM can be subdivided according to the tumor-initiating
event into hyperdiploid and non-hyperdiploid myeloma.3 While hyperdiploid MM is
defined by gains of odd-numbered chromosomes, non-hyperdiploid myeloma main-
ly harbors IGH translocations.3 Patients with high-risk cytogenetic abnormalities at
primary diagnosis, such as gain of chromosome 1q21, dele-
tion 17p (del17p) and translocation t(4;14), show inferior
outcome after high-dose therapy and autologous stem cell
transplantation (ASCT), even in the era of novel agents.4,5
Recent studies have demonstrated that disease progression
and refractoriness are caused by secondary genetic events.6,7
It has been discussed that systemic treatment might select
pre-existing aggressive subclones or cause secondary genet-
ic events and clonal evolution in patients with recurrent dis-
ease. Patients without the aforementioned abnormalities at
primary diagnosis might, therefore, relapse with cytogenet-
ically defined high-risk disease. However, there are only
limited longitudinal data available elucidating cytogenetic
changes in relapsed MM after primary therapy.6,8 We there-
fore performed a retrospective analysis of patients treated
with upfront ASCT with an interphase fluorescence in situ
hybridization (FISH) analysis of purified plasma cells at pri-
mary diagnosis and relapse. We tried to characterize cyto-
genetic evolution and studied which abnormalities occur
upon relapse. We analyzed whether baseline characteris-
tics, treatment or response affect cytogenetic evolution and




We identified 128 patients treated with ASCT for newly diag-
nosed MM with a FISH analysis at initial diagnosis (first FISH) and
relapse (second FISH). Forty-four patients were initially enrolled in
the prospective HD4 phase III trial of the German-Speaking
Myeloma Multicenter Group (GMMG, EudraCT number: 2004-
000944-26). Results of the GMMG HD4 trial have been published
previously.9 In brief, patients were randomly assigned to either the
control arm of three cycles of VAD (vincristine, doxorubicin, dex-
amethasone) followed by tandem-ASCT and thalidomide mainte-
nance for 2 years, or the experimental arm with three cycles of
PAD (bortezomib, doxorubicin, dexamethasone) followed by tan-
dem-ASCT and bortezomib maintenance therapy for 2 years.
Furthermore we identified 84 patients who were treated at our
institution outside the HD4 trial with comparable induction and
maintenance therapy regimens before and after ASCT (non-study
patients, NSP). Table 1 summarizes baseline characteristics, treat-
ment and response of both populations. The median time to sec-
ond FISH analysis from progressive disease was 7.4 months (HD4
patients) and 4.4 months (NSP). The study was performed in
accordance with the Declaration of Helsinki after informed con-
sent had been obtained. Retrospective analysis was approved by
the local ethics committee. 
Fluorescence in situ hybridization studies
FISH analyses were performed on CD138-purified plasma cells
as described previously10 at the Institute of Human Genetics at
Heidelberg University Hospital. The following probes were used:
gain1q21, gain4p16, gain5q35, gain5p15, del6q21, del8p21,
gain9q34, gain11q13, gain11q23, del13q14, gain14q32, gain15q22,
del17p13, gain19q13, del22q11, t(4;14), t(11;14), t(14;16) and a
probe for IGH splits. The threshold for all aberrations was 10%. If
an aberration was found in 10-60% of cells it was defined as sub-
clonal; if it was found in more than 60% it was defined as being
the major clone. High-risk cytogenetic abnormalities were defined
by the presence of del17p, t(4;14) or gain 1q21.
Statistical analysis
An exact McNemar test was used to assess changes between
results of FISH assessments at baseline and relapse. A Fisher exact
test was used to compare categorical parameters between groups.
A multivariable logistic regression model was fitted accounting for
baseline karyotype [hyperdiploid or t(11;14)], International Staging
System (ISS) stage, time to first progression and to second FISH
analysis, age, sex and type of induction therapy to investigate fac-
tors associated with the occurrence of high-risk cytogenetic abnor-
malities at relapse. A Wilcoxon test was used to compare time to
progression, which was measured in months and defined as time
from the start of chemotherapy to date of progression. Age in
years was analyzed as a continuous parameter. The Kaplan-Meier
method and log-rank test were used to analyze differences in over-
all survival times between patients with cytogenetic abnormalities
at both FISH assessments and at the first or second FISH only. To
analyze effects on overall survival, a multivariable Cox regression
model accounting for the same variables as mentioned above was
used. P-values <0.05 were considered statistically significant. The
last follow-up evaluations were performed in June 2016 (NSP) and
November 2015 (HD4). Analyses were carried out with R 3.3 sta-
tistical software.
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Table 1. Baseline characteristics of patients in the HD4 trial and non-study patients. 
HD 4 trial Non-study patients All
Variable Level n % n % n %
Age(median) 55.5 58.5 57.0
Sex Male 29 65.9 55 65.5 84 65.6
Female 15 34.1 29 34.5 44 34.4
ISS I 20 45.5 21 36.8 41 40.6
II 16 36.4 15 26.3 31 30.7
III 8 18.2 21 36.8 29 28.7
Induction PAD 22 50 45 53.6 67 52.3
TAD 0 0 11 13.1 11 8.6
VAD 22 50 21 25.0 43 33.6
Other 0 0 7 8.3 7 5.5
VGPR after induction 14 31.8 32 46.4 46 40.7
VGPR after ASCT 25 56.8 43 62.3 68 60.2
ISS: International Staging System; PAD:  bortezomib, doxorubicin, dexamethasone; TAD:  thalidomide, doxorubicin, dexamethasone; VAD: vincristine, doxorubicin, dexametha-
sone; VGPR: very good partial remission; ASCT: autologous stem cell transplantation.
Results
Differences between primary diagnosis and relapse
Table 2 summarizes the frequencies of cytogenetic
abnormalities detected at first, second and both FISH
examinations. The risk of developing high-risk cytogenet-
ic abnormalities was significantly higher after relapse
from ASCT [odds ratio (OR): 6.33; 95% confidence inter-
val (CI): 1.86-33.42; P<0.001]. We found an increased risk
of occurrence of del(17p) (OR: 3.4; 95% CI: 1.2-11.79;
P=0.02) and gain 1q21 (OR: 16; 95% CI: 2.49-670.96;
P<0.001). While none of the patients developed one of
the defined IGH translocations [t(4;14), t(11;14) or
t(14;16)] after relapse, IGH translocations involving an
unknown partner occurred more frequently at second
FISH only (OR: 8; 95% CI 1.07-354.98; P=0.039).
Hyperdiploidy was observed before and after ASCT in 45
patients (44.6%). Only two patients developed a de novo
hyperdiploid karyotype after relapse, while seven
patients lost the hyperdiploid karyotype during follow-
up. There were only two patients without detectable
cytogenetic abnormalities at primary diagnosis who
developed new cytogenetic abnormalities after progres-
sion. However, both patients carried a high-risk lesion at
relapse (del17p and gain 1q21, respectively).
Clonal evolution in patients with high-risk cytogenetics
Analysis of patients with gain 1q21 at first and second
FISH (n=48) revealed that most patients had subclones
that harbored different copy numbers than the main clone
(Figure 1). Five of the 16 patients with de novo gain 1q21
also had subclones with different copy numbers compared
to the main clone (Figure 1). In seven of 17 patients with
new del17p at relapse, the high-risk cytogenetic abnormal-
ity evolved as the major clone (>60% of analyzed cells). In
ten patients del17p was detected only in a subclone of
cells (10-60%). Figure 1 summarizes changes in copy num-
bers for patients with gain 1q21 and gives examples of
clonal evolution of de novo del17p.
Correlation with baseline characteristics and treat-
ment response
We could not identify any baseline cytogenetic abnor-
malities associated with the occurrence of high-risk dis-
ease at relapse. Furthermore, there were no significant dif-
ferences in high ISS stages: at baseline ISS stage 3 was
detected in 29.6% of patients without high-risk cytoge-
netic abnormalities, in 31.2% of patients with high-risk
cytogenetic abnormalities at both time points and in
33.3% of patient with high-risk cytogenetic abnormalities
only at second FISH (P=0.75). We also observed no differ-
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Figure 1. Clonal evolution in patients with gain of 1q21 and del17p. (A) Distribution of copy numbers of chromosome 1q21. Patients with increasing copy numbers
after relapse are represented in red, patients with decreasing copy numbers in blue. (B-D) Examples of clonal evolution in three patients with de novo del17p. Panel
B illustrates cause of the disease in a patient with minimal response (MR) after autologous transplantation (TPL). After relapse (PD), the second FISH analysis showed
a new del17p present in 60% of analyzed plasma cells and no significant changes of the abnormalities already present at initial diagnosis. The patient represented
in panel C achieved a very good partial remission (VGPR). The initially present hyperdiploid clone harboring a del13 and del8 was detected in a smaller subset of
analyzed plasma cells with a new, subclonal del17p. In panel D, the patient relapsed after tandem TPL and partial remission with a new del17p and MYC transloca-
tion. Compared to the patient in panel C the maternal clone could be detected in a larger proportion of plasma cells after relapse.
A B
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ences in rates of very good partial remission or better after
ASCT between the three groups (no high-risk cytogenetic
abnormalities: 53.1%, high-risk cytogenetic abnormalities
at both FISH: 67.3%, high-risk cytogenetic abnormalities
only at second FISH: 57.9%). Rates of very good partial
remission or better after ASCT were significantly higher in
patients with t(4;14) than in patients without this cytoge-
netic abnormality (92.3% versus 54.7%; P=0.01).
Multivariate analysis revealed that patients who relapsed
after ASCT and novel agent-based induction therapy had
an increased risk of developing high-risk cytogenetic
abnormalities compared to patients not treated with novel
agents during induction (OR 10.82; 95% CI: 1.65-127.66;
P=0.03).
Prognostic significance
When analyzing time to first progression based on
cytogenetic abnormalities present at baseline and
relapse, we did not observe significant differences.
Patients who developed  a de novo del17p or gain 1q21
after relapse had similar median times to progression
(29.7 and 25.8 months, respectively) as patients with
these high-risk cytogenetic abnormalities at both time
points (35.5 and 23.7 months, respectively). We observed
the same effect when analyzing overall survival in the
different groups. Figure 2 shows Kaplan-Meier estimates
for overall survival from different landmarks.
Multivariate analysis confirmed the observed effects.
Patients who developed de novo high-risk cytogenetic
abnormalities had the same risk for shorter survival [haz-
ard ratio (HR): 3.06; 95% CI: 1.09-8.59; P=0.03] as
patients with high-risk cytogenetic abnormalities already
present at baseline (HR: 3.53; 95% CI: 1.53-8.14;
P=0.003). Other factors associated with poor outcome in
the analyzed cohort were a short time to progression,
higher age and higher ISS stage. Patients with a hyper-
diploid karyotype at baseline had a better outcome (HR:
0.33; 95% CI: 0.17-0.66; P=0.002). No significant differ-
ences were observed for patients treated with novel
agents during induction or between HD4 patients or NSP.
Results from multivariate analysis from different land-
marks are summarized in Figure 2.
Discussion
The outcome of patients with MM has improved sub-
stantially during the last decades as a result of drug devel-
opment and progress in the understanding of disease
biology.11,12 However, even in the era of novel agents
some patients with high-risk cytogenetic abnormalities
or early relapse after first-line treatment have a dismal
outcome.13,14 Clonal heterogeneity and evolution are con-
tributors to disease progression and ultimately refractori-
ness in MM.6 So far, there are only limited data available
that proved clonal evolution in patients relapsing after
ASCT for newly diagnosed disease. With our current
analysis of 128 patients with FISH data at primary diag-
nosis and relapse after ASCT we demonstrate that high-
risk cytogenetic abnormalities occur more frequently at
relapse. This observation was especially due to de novo
gains of chromosome 1q and new deletions of chromo-
some 17p. No changes were observed between primary
diagnosis and relapse for defined IGH translocations,
including t(4;14).
A recent study demonstrated that chromosomal insta-
bility is a cornerstone of high-risk myeloma and propagat-
ed by bi-allelic inactivation of tumor suppressor genes,
such as TP53 located on chromosome 17p.7 Furthermore,
gain of chromosome 1q is associated with increased pro-
liferation15 (e.g. compared to hyperdiploid MM) and
genomic instability.16 Both cytogenetic abnormalities
(del17p and gain 1q21) are considered secondary events in
myelomatogenesis1 and associated with a high risk of pro-
gression from smoldering to symptomatic MM.17 Our cur-
rent study confirmed this assumption for the first time in
Cytogenetic evolution of myeloma
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Table 2. Number of patients with aberrations at first and/or second fluorescence in situ hybridization studies.
Not found Only 1st FISH Only 2nd FISH 1st and 2nd FISH
n % n % n % n %
High-risk 36 (29.8) 3 (2.5) 19 (15.7) 63 (52.1)
Gain1q21 58 (47.2) 1 (0.8) 16 (13.0) 48 (39.0)
Del17p 95 (76.6) 5 (4.0) 17 (13.7) 7 (5.6)
t(4;14) 107 (88.4) 0 0 0 0 14 (11.6)
t(11;14) 97 (80.8) 1 (0.8) 0 0 22 (18.3)
t(14;16) 109 (98.2) 0 0 0 0 2 (1.8)
t(x;14)* 107 (88.4) 0 0 8 (6.6) 6 (5.0)
Hyperdiploidy 47 (46.5) 7 (6.9) 2 (2.0) 45 (44.6)
Gain5 45 (63.4) 9 (12.7) 0 0 17 (23.9)
Gain9q34 40 (38.8) 5 (4.9) 4 (3.9) 54 (52.4)
Gain11q13 65 (55.6) 5 (4.3) 4 (3.4) 43 (36.8)
Gain11q23 17 (45.9) 4 (10.8) 3 (8.1) 13 (35.1)
Gain15q22 43 (42.2) 5 (4.9) 4 (3.9) 50 (49.0)
Gain19q13 47 (43.1) 14 (12.8) 5 (4.6) 43 (39.4)
Gain14p16 77 (63.1) 4 (3.3) 9 (7.4) 32 (26.2)
Del8p21 65 (59.1) 10 (9.1) 11 (10.0) 24 (21.8)
Del13q14 50 (39.7) 9 (7.1) 13 (10.3) 54 (42.9)
*t(x;14) = IGH translocation with unknown partner.
a large, longitudinally analyzed cohort of patients treated
with ASCT.
In contrast to the increased rates of the high-risk cytoge-
netic abnormalities del17p and gain 1q21 after relapse, we
did not observe the occurrence of new, defined IGH
translocations, including t(4;14) with its adverse implica-
tions. This is most likely due to the fact that IGH translo-
cations are considered primary, tumor-initiating events in
MM.3 However, a study by the Intergroup Francophone
Myélome found a de novo t(4;14) in 14 out of 268 patients,
while in the same study 11 patients lost the t(4;14) after
relapse.8 In accordance with our results, real time poly-
merase chain reaction analysis for IGH-MMSET con-
firmed the presence of minor t(4;14) subclones in selected
cases.8 The authors concluded that t(4;14) can evolve from
subclones, present at primary diagnosis, or can be silenced
after chemotherapy until next relapse.8 This is in line with
our finding, and those of recent studies,9 that patients with
t(4;14) show a better response to primary therapy but still
suffer from early relapse. To clarify whether clones with
high-risk cytogenetic abnormalities remain present as
minimal residual disease in patients with serological
remission, future longitudinal genome sequencing studies
in patients with relapse from minimal residual disease
negativity as well as positivity are warranted.
Sublclonal evolution was also observed in patients with
new del17p and gain 1q21. In a subset of patients, del17p
occurred only in less than 60% of analyzed plasma cells,
in line with the findings of a previous study.18
Furthermore, patients with gain 1q21 showed massive
clonal heterogeneity after relapse, since many patients had
subclones harboring different copy numbers compared to
the main clone. Future studies will have to clarify whether
the observed clonal heterogeneity in patients with del17p
or gain 1q21 might be one of the reasons for the associated
dismal outcome.
In contrast to the unchanged frequencies of the ana-
lyzed, defined IGH translocations [t(4;14), t(11;14) or
t(14;16)] after relapse, we observed higher rates of IGH
translocations with unknown partners with the IgH break-
apart probe. Translocations involving the MYC locus have
been associated with disease progression and adverse out-
come.19,20 In our cohort, only a small group of patients was
tested for MYC translocations at primary diagnosis and
relapse, so that we were unable to perform a statistical
analysis to confirm the hypothesis that MYC transloca-
tions are observed more frequently after relapse.
Furthermore, sequencing studies are warranted not only
to identify the translocation partners, but also to clarify,
whether de novo translocations are caused by class switch
recombination or by other mechanisms, as shown previ-
ously for t(11;14) and t(14;20).21
Patients with hyperdiploid MM had a favorable out-
come in our current analysis and in the majority of
patients a hyperdiploid karyotype proved to be stable
after relapse. Remarkably, seven patients lost their hyper-
diploid karyotype after relapse and gains of odd numbered
chromosomes, especially of chromosome 5, were the only
cytogenetic abnormalities occurring at lower frequencies
after relapse. This might reflect chemosensitivity of the
M. Merz et al.
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Figure 2. Multivariate survival analysis from different landmarks. Kaplan-Meier plots and multivariate analyses for overall survival in patients without high-risk cyto-
genetic abnormalities (CA) at both time points (black line), high-risk CA only at first (red line), only at second (green line) or at both (blue line) FISH analyses. Different
landmarks were used: (A) from start of chemotherapy, (B) from progressive disease, (C) from second FISH analysis.
CBA
respective hyperdiploid clones. Since patients with hyper-
diploid MM did not have a higher risk of developing high-
risk cytogenetic abnormalities, other mechanisms might
be responsible for disease progression, e.g. genomic muta-
tions or epigenetic and microenvironmental modifica-
tions. However, it must be mentioned that we defined
hyperdiploid status based on gains of the aforementioned
odd-numbered chromosome loci. To rule out whether
abnormalities other than the analyzed trisomies occurred
after relapse, we would have had to include whole
genome screening methods, such as single-nucleotide
polymorphism assays.22
We could not identify other baseline characteristics or
cytogenetic abnormalities associated with the occurrence
of high-risk cytogenetic abnormalities at relapse and treat-
ment response in patients with new del17p or gain 1q21
did not differ between patients with or without these
cytogenetic abnormalities at both time points.
Multivariate analysis revealed that patients who relapsed
after novel agent-based induction therapy were at higher
risk of developing the aforementioned cytogenetic abnor-
malities.
Since the first novel agents were combined with ASCT
for the treatment of MM, physicians have debated
whether relapses from primary therapy are becoming
more aggressive. It has been suggested that the rates of
extramedullary disease after novel agent-based treatment
are higher23 and early relapse after primary therapy with
novel agents is still associated with poor outcome.14 With
our current analysis we provide the first evidence that
relapse after treatment with novel agents might result in
higher rates of high-risk cytogenetic abnormalities. One
explanation for this finding might be that effective treat-
ment selects pre-existing aggressive subclones that are
below the level of sensitivity of FISH analyses, as pro-
posed in the Intergroup Francophone Myélome study on
t(4;14).8 Another explanation might be that chromosomal
instability propagates disease progression and causes sec-
ondary genetic events.24
Lastly, we investigated the prognostic significance of
new cytogenetic abnormalities after relapse. We found that
patients with de novo del17p or gain 1q21 had the same dis-
mal outcome as patients with the respective cytogenetic
abnormalities detected at both time points. In fact, time to
first progression was not significantly shorter whether the
respective aberrations were already present at primary
diagnosis or not. Again, this could imply that the evolving
high-risk clone after relapse might have already been pres-
ent at a subclonal level at primary diagnosis.
There are several potential criticisms of the current
study that need to be addressed in the future. First of all,
although patients were uniformly treated with ASCT,
there were substantial differences in pre-transplant induc-
tion therapy in the cohort analyzed. Some patients were
treated with proteasome inhibitors or immunomodulato-
ry drugs before and/or after ASCT while others received
only conventional chemotherapy. This might have caused
different selection pressures on pre-existing clones and –
more importantly – might have caused different second-
ary genetic events, since treatment with immunomodula-
tory drugs, in particular, has been associated with the
occurrence of cytogenetic abnormalities typical of
myelodysplastic syndromes.25 This hampers the compari-
son of study and non-study patients within our analysis.
Secondly, our retrospective data included only 128
patients and all patients had relapsed at the time of the
second FISH. The findings for some subgroups are, there-
fore, based on very small numbers and we did not have a
validation cohort of patients with a second FISH analysis
in remission after ASCT. This weakness could be over-
come in future studies including pre-planned bone mar-
row aspirates with FISH at certain time-points in a
prospective clinical trial, e.g. at primary diagnosis, after
ASCT before maintenance, at the end of maintenance and
relapse. In this way, a longitudinal comparison of changes
in the genetic profile of patients in remission and relapse
would be possible. Lastly, as mentioned above, we will
investigate the partners of the so far unknown IGH
translocations observed after relapse in our current study.
In summary, our findings underline the importance of
FISH analyses at relapse. We demonstrate that cytogenetic
analyses need to be repeated, since the risk profile might
be worse after treatment than at baseline, especially in the
era of novel agents.3
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